3 Marijuana Stocks That Could Surprise on the ‘High’ Side

The marijuana stocks on our list might see 75%+ earnings growth in the upcoming quarter 

SmallCapPower | January 17, 2017: There has been a frenzy of activity to capitalize on the budding marijuana sector in Canada, with Shoppers Drug Mart recently applying for a marijuana license and cannabis dispensaries sprouting up throughout the country. Today, we have identified a few high-growth marijuana stocks expected to beat earnings estimates this reporting season.

Win Big With Our Small Cap Picks


OrganiGram Holdings Inc. (TSX: OGI) – $2.68

OrganiGram Holdings Inc., formerly Inform Exploration Corp., is a Canada-based company that operates through its subsidiary Organigram Inc. Organigram Inc. is a licensed medical marijuana producer as regulated by Health Canada under the Marijuana Medical Access Regulations (MMAR) of the Government of Canada.

  • Market Cap: $270 million
  • Expected Report Date (FQ1): 27/01/2017
  • Expected Growth in EPS (FY1): 75%
  • 52-Week Total Return: +222.9%

Aurora Cannabis Inc. (TSXV: ACB) – $2.50

Aurora Cannabis Inc. is engaged in the production and sale of medical cannabis, as well as distributing medical marijuana pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company’s product types include Tetrahydrocannabinol (THC), Cannabidiole (CBD), indica, sativa and hybrid. The CBD product is connected to the anti-inflammatory, pain relieving, anti-nausea, anti-anxiety and muscle relaxing functions of medical marijuana.

  • Market Cap: $714 million
  • Expected Report Date (FQ1): 28/02/2017
  • Expected Growth in EPS (FY1): 100%
  • 52-Week Total Return: +363.0%

Aphria Inc. (TSXV: APH) – $5.43

Aphria Inc., formerly Black Sparrow Capital Corp. is a Canada-based company, which is engaged in producing and selling medical marijuana through retail sales and wholesale channels. The Company’s retail sales are sold primarily through its online store, as well as telephone orders. Its wholesale shipments are sold to other Medical Purposes Regulations (MMPR) Licensed Producers. It offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil.

  • Market Cap: $609 million
  • Expected Report Date (FQ1): 19/04/2017
  • Expected Growth in EPS (FY1): 200%
  • 52-Week Total Return: +352.5%